
Tarloxotinib (CHEM132664)
| Record Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Version | 1.0 | ||||||||
| Creation Date | 2026-04-14 20:01:12 UTC | ||||||||
| Update Date | 2026-08-22 03:06:08 UTC | ||||||||
| Accession Number | CHEM132664 | ||||||||
| Identification | |||||||||
| Common Name | Tarloxotinib | ||||||||
| Class | Small Molecule | ||||||||
| Description | Tarloxotinib is an organoheterocyclic compound with the formula C24H24BrClN9O3. Tarloxotinib belongs to the pyrido[3,4-d]pyrimidines, a subclass of pyridopyrimidines within the organic compounds. With an average molecular weight of 601.87 g/mol, Tarloxotinib is a heavy molecule. This compound acts as an inhibitor of two recorded protein targets: the epidermal growth factor receptor (EGFR) and the receptor tyrosine-protein kinase erbB-2 (ERBB2). | ||||||||
| Contaminant Sources | Not Available | ||||||||
| Contaminant Type | Not Available | ||||||||
| Chemical Structure | |||||||||
| Synonyms | Not Available | ||||||||
| Chemical Formula | C24H24BrClN9O3 | ||||||||
| Average Molecular Mass | 601.870 g/mol | ||||||||
| Monoisotopic Mass | 600.087 g/mol | ||||||||
| CAS Registry Number | 1636938-13-0 | ||||||||
| IUPAC Name | [(2E)-3-({4-[(3-bromo-4-chlorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl}carbamoyl)prop-2-en-1-yl]dimethyl[(1-methyl-4-nitro-1H-imidazol-5-yl)methyl]azanium | ||||||||
| Traditional Name | Not Available | ||||||||
| SMILES | CN1C=NC(=C1C[N+](C)(C)C\C=C\C(=O)NC1=NC=C2N=CN=C(NC3=CC(Br)=C(Cl)C=C3)C2=C1)[N+]([O-])=O | ||||||||
| InChI Identifier | InChI=1S/C24H23BrClN9O3/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36)/p+1/b5-4+ | ||||||||
| InChI Key | MUJMYVFVAWFUJL-SNAWJCMRSA-O | ||||||||
| Chemical Taxonomy | |||||||||
| Classification | Not classified | ||||||||
| Biological Properties | |||||||||
| Status | Detected and Not Quantified | ||||||||
| Origin | Not Available | ||||||||
| Cellular Locations | Not Available | ||||||||
| Biofluid Locations | Not Available | ||||||||
| Tissue Locations | Not Available | ||||||||
| Pathways | Not Available | ||||||||
| Applications | Not Available | ||||||||
| Biological Roles | Not Available | ||||||||
| Chemical Roles | Not Available | ||||||||
| Physical Properties | |||||||||
| State | Not Available | ||||||||
| Appearance | Not Available | ||||||||
| Experimental Properties |
| ||||||||
| Predicted Properties | Not Available | ||||||||
| Spectra | |||||||||
| Spectra |
| ||||||||
| Toxicity Profile | |||||||||
| Route of Exposure | Not Available | ||||||||
| Mechanism of Toxicity | Not Available | ||||||||
| Metabolism | Not Available | ||||||||
| Toxicity Values | Not Available | ||||||||
| Lethal Dose | Not Available | ||||||||
| Carcinogenicity (IARC Classification) | Not Available | ||||||||
| Uses/Sources | Not Available | ||||||||
| Minimum Risk Level | Not Available | ||||||||
| Health Effects | Not Available | ||||||||
| Symptoms | Not Available | ||||||||
| Treatment | Not Available | ||||||||
| Concentrations | |||||||||
| Not Available | |||||||||
| External Links | |||||||||
| Identifiers | Not Available | ||||||||
| References | |||||||||
| Synthesis Reference | Not Available | ||||||||
| MSDS | Not Available | ||||||||
| General References | Not Available | ||||||||